Raia Drogasil's Q2 Growth Is Real-But Is the Market Paying Too Much for Digital and GLP-1?

Raia Drogasil delivered solid Q2 growth, but the valuation debate starts after the release

RADLY's second quarter was strong, but the stock may now be pricing in more than this level of execution alone justifies.

The debate is about price as much as quality

The market's first reaction was positive: shares rose 5.56% after the earnings release. The operating results still point to steady progress rather than a spectacular beat. Net revenue reached about R$11 billion, up 9.8%, adjusted EBITDA was R$1.017 billion, and adjusted net income was R$432.7 million, up 7.4%. For a mature pharmacy operator, that is solid. It supports the thesis that Raia Drogasil is executing well, but it does not close the debate on its own.

RD Saúde also reported gross revenue of R$12.8 billion, up 18.3%, in its presentation materials. That is a different frame from the reported net revenue figure, so it is useful to keep both in view rather than treat either one as the whole story.

The core split is clear. The core business still appears to be improving-adjusted net income excluding 4Bio was R$424 million, up 23.4%-but investors still have to decide how much of that improvement is already reflected in the share price. From here, the most important test is whether stronger operating performance keeps showing up quarter after quarter.

Raia Drogasil's moat looks wider, not just its sales

The key question is no longer whether RADLY can grow. It can. The more important question is whether the business is becoming harder to dislodge.

Store growth and customer reach are reinforcing each other

RD Saúde ended June with 3,687 pharmacies after 76 new openings and 3 closures. That matters because each store is not just a sales point. It can also serve as a pickup location, a service counter, and a touchpoint that strengthens the company's digital and loyalty ecosystems. Added to an active customer base of 53 million over the last twelve months, that footprint can make the network more valuable as omnichannel habits deepen.

Full ownership of Stix gives RD Saúde more control over customer insight

RD Saúde took full control of loyalty program Stix by buying the 66.67% stake held by GPA for R$23 million. The strategic point matters more than the size of the check. With full ownership, the company has clearer control over the link between purchases, rewards, and customer data. If that translates into better targeting, more repeat visits, and stronger retention, the advantage is not only physical distribution. It is also customer insight.

The consumer base is large, but GLP-1 claims still need operating proof

The underlying audience is already big, with 47.5 million active customers in the ecosystem. That gives Raia Drogasil a plausible route to benefit from growing demand around weight-management therapies, adherence support, and related categories. But the bigger point is operational, not narrative: a dense store network, loyalty data, and omnichannel tools can help the company capture that demand more effectively if management can turn it into sustained mix and share gains.

What would validate the premium, and what would challenge it

RADLY still looks like a quality retail pharmacy franchise. The next few months should show whether investors are paying for operating durability or advancing too far against future stories.

Signals that would support the bull case

• Another quarter of strong existing-store performance, with mature-store sales growth and overall volume-and-mix gains continuing to outperform the regulated-price backdrop.
• Accelerating digital sales turning into repeat customer behavior rather than a one-quarter headline.
• Strong Branded Rx growth and category-mix momentum becoming more durable, giving GLP-1 exposure more operating substance.
• Continued margin stability and healthy cash generation, which would make a premium valuation easier to defend.

Signals that would weaken it

• A wider gap between gross revenue and net revenue without a clear explanation could keep the valuation debate alive.
• If stable profitability margins stop looking stable, the market may treat growth as more expensive than it currently appears.
• If significantly improving cash generation fades, the case for paying up for future digital or wellness optionality weakens directly.
• If full control of Stix does not eventually show up in repeat purchasing or retention, the business will have to justify the loyalty investment through ordinary retail metrics.

The next release cycle, beginning with the scheduled 2Q26 Earnings Release and Conference Call, should provide the next clear window to judge whether execution is catching up with the story-or whether the stock has simply gotten ahead of it.